Chimeric receptors with 4-1BB stimulatory signaling domain

• US 20050113564A1
• Filed: 11/04/2004
• Published: 05/26/2005
• Est. Priority Date: 11/05/2003
• Status: Abandoned Application

• Current Assignee: St Jude Children's Research Hospital Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: St Jude Children's Research Hospital Incorporated (Abbott Laboratories Incorporated)
• Inventors: Imai, Chihaya, Campana, Dario
• Application Number:
  US10/981,352
• Publication Number:
  US 20050113564A1
• Time in Patent Office: Days
• US Class Current: 530/350
• CPC Class Codes: C07K 14/70517 CD8
• CPC Class Codes: C07K 14/70578 NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 NGF-receptor C07K14/71, TNF-receptor C07K14/7151
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/03 containing a transmembrane segment

Abstract

The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use. Also included is a method for obtaining an enriched population of NK cells from a mixed population of NK cells and T cells.

Claims

1. A chimeric receptor comprising an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic domain, wherein said cytoplasmic domain comprises the signaling domain of 4-1BB.

2. The chimeric receptor of claim 1 wherein said 4-1BB is human 4-1BB.

3. The chimeric receptor of claim 2 wherein said human 4-1BB has the amino acid sequence set forth in SEQ ID NO:

2.

4. The chimeric receptor of claim 3 wherein said signaling domain comprises amino acids 214 to 255 of SEQ ID NO:

2.

5. The chimeric receptor of claim 1 wherein said cytoplasmic domain further comprises the signaling domain of CD3ζ

.

6. The chimeric receptor of claim 1 wherein said extracellular ligand binding domain comprises a single chain variable domain of an anti-CD19 monoclonal antibody.

7. The chimeric receptor of claim 1 wherein said transmembrane domain comprises the transmembrane domain of CD8α

.

8. A polynucleotide encoding the chimeric receptor of claim 1.

9. A vector for recombinant expression of a chimeric receptor, said vector comprising the polynucleotide of claim 8, operatively linked to at least one regulatory element in the appropriate orientation for expression.

10. A host cell expressing the chimeric receptor of claim 1.

11. The host cell of claim 10 selected from the group consisting of T lymphocytes and natural killer (NK) cells.

12. A chimeric receptor having a cytoplasmic domain comprising the signaling domain of 4-1BB.

13. The chimeric receptor of claim 12 wherein said 4-1BB is human 4-1BB.

14. The chimeric receptor of claim 13 wherein said human 4-1BB has the amino acid sequence set forth in SEQ ID NO:

2.

15. The chimeric receptor of claim 14 wherein said signaling domain comprises amino acids 214 to 255 of SEQ ID NO:

2.

16. A method of enhancing T lymphocyte or natural killer cell activity of an individual by introducing into said individual a T lymphocyte or natural killer cell comprising a chimeric receptor having a cytoplasmic domain comprising the signaling domain of 4-1BB.

17. A method for treating an individual suffering from cancer by introducing into said individual a T lymphocyte or natural killer cell comprising a chimeric receptor wherein said chimeric receptor comprises an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic domain, wherein said cytoplasmic domain comprises the signaling domain of 4-1BB.

18. The method of claim 17 wherein the cancer is selected from the group consisting of lung cancer, melanoma, breast cancer, prostate cancer, colon cancer, renal cell carcinoma, ovarian cancer, neuroblastoma, rhabdomyosarcoma, leukemia and lymphoma.

19. The method of claim 17 wherein the extracellular ligand binding domain comprises a single chain variable domain of an anti-CD19 monoclonal antibody.

20. The method of claim 19 wherein the cancer is of B cell origin.

21. The method of claim 20 wherein the cancer is selected from the group consisting of B-lineage acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia and B-cell non-Hodgkin'"'"'s lymphoma.

22. A cell line comprising cells that activate natural killer (NK) cells, lack or poorly express major histocompatibility complex I molecules and do not activate T lymphocytes wherein such NK activating cells express membrane bound interleukin-15 and a co-stimulatory factor ligand.

23. The cell line of claim 22 wherein said cell line also lack or poorly expresses major histocampatibility complex II molecules.

24. The cell line of claim 23 wherein the NK activating cells are selected from the group consisting of K562 myeloid leukemia cells and WFWT Wilms tumor cells.

25. The cell line of claim 22 wherein the co-stimulatory factor ligand is CD137L.

26. A method of expanding natural killer (NK) cells which comprises culturing a population of cells comprising NK cells with a cell line that activates NK cells, wherein the cell line that activates NK cells expresses membrane bound interleukin-15 and a co-stimulatory factor ligand.